STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

  • Elisabet Cuyàs, Almudena Pérez-Sánchez, Vicente Micol, Javier A. Menendez, Joaquim Bosch-Barrera
  • Cell Cycle, October 2016, Taylor & Francis
  • DOI: 10.1080/15384101.2016.1245249

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1080/15384101.2016.1245249